{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T10:25:13Z","timestamp":1743589513138},"reference-count":43,"publisher":"Geotar-Media Publishing Group","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Angiol Sosud Khir"],"published-print":{"date-parts":[[2020]]},"DOI":"10.33529\/angio2020106","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T15:43:21Z","timestamp":1585928601000},"page":"165","source":"Crossref","is-referenced-by-count":2,"title":["Ways of decreasing incidence of complications in patients after endured reconstructive and endovascular operations on lower limb arteries"],"prefix":"10.33029","volume":"26","author":[{"given":"V. S.","family":"Arakelian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18453","reference":[{"key":"key-10.33529\/ANGIO2020106-1","doi-asserted-by":"crossref","unstructured":"Fowkes F.G., Rudan D., Rudan I., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382: 1329-1340.","DOI":"10.1016\/S0140-6736(13)61249-0"},{"key":"key-10.33529\/ANGIO2020106-2","doi-asserted-by":"crossref","unstructured":"Go A.S., Mozaffarian D., Roger V.L., et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013; 127: 143-152.","DOI":"10.1161\/CIR.0b013e318282ab8f"},{"key":"key-10.33529\/ANGIO2020106-3","unstructured":"McDermott M.M., Greenland P., Liu K., et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. 2001; 286: 1599-1606."},{"key":"key-10.33529\/ANGIO2020106-4","doi-asserted-by":"crossref","unstructured":"Pande R.L., Perlstein T.S., Beckman J.A., Creager M.A. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011; 124: 17-23.","DOI":"10.1161\/CIRCULATIONAHA.110.003954"},{"key":"key-10.33529\/ANGIO2020106-5","doi-asserted-by":"crossref","unstructured":"Smith G.D., Shipley M.J., Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation. 1990; 82: 1925-1931.","DOI":"10.1161\/01.CIR.82.6.1925"},{"key":"key-10.33529\/ANGIO2020106-6","doi-asserted-by":"crossref","unstructured":"Sigvant B., Hasvold P., Kragsterman B., et al. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. J. Vasc. Surg. 2017; 66: 2: 507-514.","DOI":"10.1016\/j.jvs.2017.01.067"},{"key":"key-10.33529\/ANGIO2020106-7","doi-asserted-by":"crossref","unstructured":"Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. 1992; 326: 6: 381-386.","DOI":"10.1056\/NEJM199202063260605"},{"key":"key-10.33529\/ANGIO2020106-8","doi-asserted-by":"crossref","unstructured":"Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care. JAMA. 2001; 11: 1317-1324.","DOI":"10.1001\/jama.286.11.1317"},{"key":"key-10.33529\/ANGIO2020106-9","unstructured":"Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg. 2007; 45: 5-67."},{"key":"key-10.33529\/ANGIO2020106-10","doi-asserted-by":"crossref","unstructured":"Savel'ev V.S., Koshkin V.M., Karalkin A.V. Patogenez i konservativnoe lechenie tyazhelykh stadii obliteriruyushchego ateroskleroza arterii nizhnikh konechnostei. Moskva: MIA. 2010; 214. (in Russ.)","DOI":"10.1177\/1944451610378133"},{"key":"key-10.33529\/ANGIO2020106-11","unstructured":"Dzhaff M.R., Moler E.R. Zabolevaniya perifericheskikh arterii. Moskva: GEOTAR-Media. 2010; 224. (in Russ.)"},{"key":"key-10.33529\/ANGIO2020106-12","unstructured":"Kharazov A.F., Kolyaev A.O., Isaev A.A. Rasprostranennost' simptomnoi ishemii nizhnikh konechnostei v Rossiiskoi Federatsii. Khirurgiya. 2016; 7: 68-71. (in Russ.)"},{"key":"key-10.33529\/ANGIO2020106-13","unstructured":"Polyakov P.I., Gorelik S.G., Zheleznova E.A. Obliteriruyushchii ateroskleroz nizhnikh konechnostei u lits starcheskogo vozrasta. Vestnik novykh meditsinskikh tekhnologii. 2013; 20: 1: 98-101. (in Russ.)"},{"key":"key-10.33529\/ANGIO2020106-14","unstructured":"Mahoney E.M., Wang K., Keo H.H., et al. Vascular Hospitalization Rates and Costs in Patients With Peripheral Artery Disease in the United States. Circ. Cardiovasc. Qual. Outcomes. 2010; 3: 642-651."},{"key":"key-10.33529\/ANGIO2020106-15","doi-asserted-by":"crossref","unstructured":"Bonaca M.P., Gutierrez J.A., Creager M.A., et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial. Circulation. 2016; 133: 997-1005.","DOI":"10.1161\/CIRCULATIONAHA.115.019355"},{"key":"key-10.33529\/ANGIO2020106-16","doi-asserted-by":"crossref","unstructured":"Jones W.S., Baumgartner I., Hiatt W.R., et al. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation. 2017; 135: 3: 241-250.","DOI":"10.1161\/CIRCULATIONAHA.116.025880"},{"key":"key-10.33529\/ANGIO2020106-17","doi-asserted-by":"crossref","unstructured":"Kumbhani D.J., Steg P.G., Cannon C.P., et al. REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur. Heart J. 2014; 35: 2864-2872.","DOI":"10.1093\/eurheartj\/ehu080"},{"key":"key-10.33529\/ANGIO2020106-18","unstructured":"Duval S., Keo H.H., Oldenburg N.C., et al. The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: the FRIENDS registry. Am. Heart J. 2014; 168: 577-587."},{"key":"key-10.33529\/ANGIO2020106-19","unstructured":"Bonaca M.P., Bhatt D.L., Storey R.F., et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J. Am. Coll. Cardiol. 2016; 67: 2719-2728."},{"key":"key-10.33529\/ANGIO2020106-20","doi-asserted-by":"crossref","unstructured":"Hiatt W.R., Fowkes F.G., Heizer G., Berger J.S., et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N. Engl. J. Med. 2017; 376: 5: 32-40.","DOI":"10.1056\/NEJMoa1611688"},{"key":"key-10.33529\/ANGIO2020106-21","doi-asserted-by":"crossref","unstructured":"Howard D.P., Banerjee A., Fairhead J.F., et al. Population-Based Study of Incidence, Risk Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events: Implications for Prevention. Circulation. 2015; 132: 1805-1815.","DOI":"10.1161\/CIRCULATIONAHA.115.016424"},{"key":"key-10.33529\/ANGIO2020106-22","doi-asserted-by":"crossref","unstructured":"Anand S.S., Caron F., Eikelboom J., et al. Major Adverse Limb Events in Lower Extremity Peripheral Artery Disease: COMPASS Trial. Journal of the American College of Cardiology. 2018; 71: 20: 2306-2315.","DOI":"10.1016\/j.jacc.2018.03.008"},{"key":"key-10.33529\/ANGIO2020106-23","unstructured":"Hirsch A.T., Van\u2019t Hof J.R., Bonaca M. The conundrum of ALI and systemic embolic events: seeing our way to improved vascular health. Vasc. Med. 2016; 21: 535-538."},{"key":"key-10.33529\/ANGIO2020106-24","unstructured":"Stern J.R., Wong C.K., Yerovinkina M., et al. A meta-analysis of long-term mortality and associated risk factors following lower extremity amputation. Ann. Vasc. Surg. 2017; 42: 322-327."},{"key":"key-10.33529\/ANGIO2020106-25","unstructured":"Swaminathan A., Vemulapalli S., Patel M.R., Jones W.S. Lower extremity amputation in peripheral artery disease: improving patient outcomes. Vasc. Health Risk Manag. 2014; 10: 417-424."},{"key":"key-10.33529\/ANGIO2020106-26","unstructured":"Hess C.N., Norgren L., Ansel G.M., et al. A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) initiative. Circulation..2017; 135: 2534-2555."},{"key":"key-10.33529\/ANGIO2020106-27","doi-asserted-by":"crossref","unstructured":"Alonso-Coello P., Bellmunt S., McGorrian C., et al. Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (suppl): 669-690.","DOI":"10.1378\/chest.141.4.1129b"},{"key":"key-10.33529\/ANGIO2020106-28","unstructured":"Tendera M., Aboyans V., et al. ESC (European Stroke Organisation), Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Trea. Eur. Heart J. 2011; 32: 2851-2906."},{"key":"key-10.33529\/ANGIO2020106-29","unstructured":"Gerhard-Herman M.D., Gornik H.L., Barrett C., et al. 2016 AHA\/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines..Circulation. 2017; 135: 726-779."},{"key":"key-10.33529\/ANGIO2020106-30","unstructured":"Anand S., Yusuf S., Montague P., et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N. Engl. J. Med. 2007; 357: 217-227."},{"key":"key-10.33529\/ANGIO2020106-31","unstructured":"Berger J.S., Ladap J.A. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. J. Am. Coll. Cardiol. 2017; 69: 2293-2300."},{"key":"key-10.33529\/ANGIO2020106-32","doi-asserted-by":"crossref","unstructured":"Tangelder M.J.D., Algra A., Lawson, J.A., et al. The Dutch Bypass Oral Anticoagulants or Aspirin Study. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery: a randomised trial. Lancet. 2000; 355: 346-351.","DOI":"10.1016\/S0140-6736(99)07199-8"},{"key":"key-10.33529\/ANGIO2020106-33","unstructured":"Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 2006; 354: 1706-1717."},{"key":"key-10.33529\/ANGIO2020106-34","unstructured":"Gent M., Beaumont D., Blanchard J., et al. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348: 329-339."},{"key":"key-10.33529\/ANGIO2020106-35","doi-asserted-by":"crossref","unstructured":"Bonaca M.P., Scirica B.M., Creager M.A., et al. Vorapaxar in patients with peripheral artery disease: results from TRA2\u0454P-TIMI 50. Circulation. 2013; 127: 1522-1529.","DOI":"10.1161\/CIRCULATIONAHA.112.000679"},{"key":"key-10.33529\/ANGIO2020106-36","doi-asserted-by":"crossref","unstructured":"Cacoub P.P., Bhatt D.L., Steg P.G., et al. CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur. Heart J. 2002; 30: 192-201.","DOI":"10.1093\/eurheartj\/ehn534"},{"key":"key-10.33529\/ANGIO2020106-37","doi-asserted-by":"crossref","unstructured":"Anand S.S., Bosch J., Eikelboom J.W., et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391: 219-229.","DOI":"10.1016\/S0140-6736(17)32409-1"},{"key":"key-10.33529\/ANGIO2020106-38","unstructured":"Prins M.H., Lensing A.W., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb. J. 2013; 11: 21."},{"key":"key-10.33529\/ANGIO2020106-39","unstructured":"Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365: 883-891."},{"key":"key-10.33529\/ANGIO2020106-40","unstructured":"Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008; 358: 2765-2775."},{"key":"key-10.33529\/ANGIO2020106-41","unstructured":"Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 2012; 366: 9-19."},{"key":"key-10.33529\/ANGIO2020106-42","unstructured":"Bosch J., Eikelboom J.W., Connolly S.J., et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Can. J. Cardiol. 2017; 33: 1027-1035."},{"key":"key-10.33529\/ANGIO2020106-43","doi-asserted-by":"crossref","unstructured":"Connolly S.J., Eikelboom W., Bosch J., et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391: 205-218.","DOI":"10.1016\/S0140-6736(17)32458-3"}],"container-title":["Angiology and vascular surgery"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T14:56:49Z","timestamp":1666277809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.elibrary.ru\/item.asp?id=42461368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["ANGIO2020106"],"URL":"https:\/\/doi.org\/10.33529\/angio2020106","relation":{},"ISSN":["1027-6661"],"issn-type":[{"value":"1027-6661","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}